PMID- 16112026
OWN - NLM
STAT- MEDLINE
DCOM- 20051207
LR  - 20071114
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 66
IP  - 7
DP  - 2005 Jul
TI  - Extinction of the human leukocyte antigen homozygosity effect after two doses of 
      the measles-mumps-rubella vaccine.
PG  - 788-98
AB  - We have reported associations between human leukocyte antigen (HLA) homozygosity 
      and low measles antibody levels after one dose of the measles, mumps, and rubella 
      (MMR) vaccine. Here, we examined associations between HLA homozygosity and immune 
      responses to MMR after two doses of vaccine. We examined associations between HLA 
      homozygosity and measles antibody levels in a group of 178 children (cohort 1) as 
      well as associations between homozygosity and antibody levels and 
      lymphoproliferative responses to MMR in 346 children (cohort 2). In cohort 1, HLA 
      homozygotes and heterozygotes had similar increases in measles antibody levels 
      after a second dose of measles vaccine. In cohort 2, HLA homozygosity was not 
      associated with measles immune measures after two doses of vaccine. Homozygosity 
      at the DPB locus was associated with increased rubella antibody levels, and 
      homozygosity at the class IA alleles was associated with lower mumps 
      lymphoproliferative response. Homozygosity at increasing numbers of loci was also 
      associated with lower mumps antibody levels and lymphoproliferative response. 
      Therefore, two doses of the MMR vaccine appear to induce sufficient antibody 
      levels and lymphoproliferative responses against measles and rubella, regardless 
      of HLA homozygosity status. However, children who are HLA homozygous may be less 
      protected against mumps compared with children who are heterozygous.
FAU - St Sauver, Jennifer L
AU  - St Sauver JL
AD  - Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, 
      Rochester, MN 55905, USA.
FAU - Dhiman, Neelam
AU  - Dhiman N
FAU - Ovsyannikova, Inna G
AU  - Ovsyannikova IG
FAU - Jacobson, Robert M
AU  - Jacobson RM
FAU - Vierkant, Robert A
AU  - Vierkant RA
FAU - Pankratz, V Shane
AU  - Pankratz VS
FAU - Jacobsen, Steven J
AU  - Jacobsen SJ
FAU - Poland, Gregory A
AU  - Poland GA
LA  - eng
GR  - AI 33144/AI/NIAID NIH HHS/United States
GR  - AI 48793/AI/NIAID NIH HHS/United States
GR  - AR030582/AR/NIAMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Antibodies)
RN  - 0 (Antibodies, Viral)
RN  - 0 (HLA Antigens)
RN  - 0 (Measles-Mumps-Rubella Vaccine)
RN  - 0 (rubella antibodies)
SB  - IM
MH  - Antibodies/immunology
MH  - Antibodies, Viral/immunology
MH  - Antibody Formation/immunology
MH  - Child
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HLA Antigens/*genetics/immunology
MH  - Heterozygote
MH  - Homozygote
MH  - Humans
MH  - Immunity, Cellular/immunology
MH  - Infant
MH  - Leukocytes, Mononuclear/immunology
MH  - Lymphocyte Activation/immunology
MH  - Male
MH  - Measles/immunology/prevention & control
MH  - Measles-Mumps-Rubella Vaccine/administration & dosage/*immunology
MH  - Mumps/immunology/prevention & control
MH  - Rubella/immunology/prevention & control
EDAT- 2005/08/23 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/08/23 09:00
PHST- 2004/01/11 00:00 [received]
PHST- 2005/03/11 00:00 [revised]
PHST- 2005/03/14 00:00 [accepted]
PHST- 2005/08/23 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/08/23 09:00 [entrez]
AID - S0198-8859(05)00070-4 [pii]
AID - 10.1016/j.humimm.2005.03.008 [doi]
PST - ppublish
SO  - Hum Immunol. 2005 Jul;66(7):788-98. doi: 10.1016/j.humimm.2005.03.008.